News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Industry Veteran John Kaiser Joins C8 MediSensors, Inc.


1/8/2013 6:49:37 AM

SAN JOSE, Calif., Jan. 7, 2013 /PRNewswire/ -- C8 MediSensors, Inc. (www.c8medisensors.com), today announced that industry veteran John Kaiser has joined the company as its new Chief Executive Officer.

(Logo: http://photos.prnewswire.com/prnh/20120406/AQ83655LOGO)

Mr. Kaiser takes the reins from Paul Zygielbaum, a C8 MediSensors co-founder who guided the company as CEO though 2012, but is stepping aside for medical reasons. Mr. Zygielbaum will continue to contribute significantly to the organization as he has for the past nine years.

Mr. Kaiser has thirty years' experience in the medical device sector. After starting his early career with Abbott Diagnostics, John worked at Boehringer Mannheim (now part of Roche) for a decade in successive positions including Vice President of two key divisions. During this time, John and Boehringer launched the world's first blood-based glucose diagnostics, a business that ultimately grew into the $4 billion glucose/diagnostics business purchased by Roche.

Subsequently, John was then CEO & Chairman of BioCircuits Corp, then Founder and CEO of Vetmedsupply, and later CEO of Aperon Biosystems. For the past two years, John has worked with various venture firms on several medical technology business plans and diligence. He also was a member of the Sensys Medical board of directors for many years, so with this and his long tenure at Boehringer Mannheim in diabetes, he brings great domain expertise in the diabetes sector.

John has served on other boards and in other positions throughout the device and healthcare sector and participated in the commercialization of many medical products.

About C8 MediSensors

Headquartered in San Jose CA, C8 MediSensors' breakthrough patent-protected technology gives people with diabetes a continuous view of their glucose levels without the pain, inconvenience and high cost of invasive continuous glucose monitoring. Visit www.c8medisensors.com.

This document contains forward-looking statements. Any statements contained in this document that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to C8 MediSensors' anticipated product sales and financing needs. These forward-looking statements are based upon C8 MediSensors' current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with market conditions, customer demand for theproduct, and risks and uncertainties associated with C8 MediSensors' business and finances in general. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. C8 MediSensors does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

SOURCE C8 MediSensors, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES